###begin article-title 0
###xml 69 77 <span type="species:ncbi:9606">patients</span>
Pulmonary and systemic hepatocyte and keratinocyte growth factors in patients with chronic obstructive pulmonary disease
###end article-title 0
###begin title 1
Background
###end title 1
###begin p 2
###xml 287 295 <span type="species:ncbi:9606">patients</span>
The potential role of growth factors in chronic obstructive pulmonary disease (COPD) has begun to be addressed only recently and is still poorly understood. For this study, we investigated potential abnormalities of hepatocyte growth factor (HGF) and keratinocyte growth factor (KGF) in patients with COPD.
###end p 2
###begin title 3
Methods
###end title 3
###begin p 4
###xml 241 242 239 240 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 350 351 342 343 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 164 172 <span type="species:ncbi:9606">patients</span>
To this end, we compared the levels of HGF and KGF, measured by enzyme-linked immunosorbent assay (ELISA), in bronchoalveolar lavage (BAL) fluid and in serum in 18 patients with COPD (62 +/- 9 yrs, forced expiratory volume in one second [FEV1] 57 +/- 12% ref, X +/- standard deviation of mean), 18 smokers with normal lung function (58 +/- 8 yrs, FEV1 90 +/- 6% ref) and 8 never smokers (67 +/- 9 yrs, 94 +/- 14% ref).
###end p 4
###begin title 5
Results
###end title 5
###begin p 6
###xml 48 56 <span type="species:ncbi:9606">patients</span>
We found that in BAL, HGF levels were higher in patients with COPD than in the other two groups whereas, in serum, HGF concentration was highest in smokers with normal lung function (p < 0.01). KGF levels were not significantly different between groups, neither in blood nor in BAL (most values were below the detection limit).
###end p 6
###begin title 7
Conclusions
###end title 7
###begin p 8
These results highlight a different response of HGF in BAL and serum in smokers with and without COPD that may be relevant for tissue repair in COPD.
###end p 8
###begin title 9
Introduction
###end title 9
###begin p 10
###xml 274 289 274 289 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b20-copd-3-719">Rabe et al 2007</xref>
###xml 257 264 <span type="species:ncbi:4097">tobacco</span>
Chronic obstructive pulmonary disease (COPD) is characterized by extensive lung damage, which is believed to result from the abnormal inflammatory response that occurs in the so-called susceptible smokers in response to inhaled particles and gases, mostly, tobacco smoking (Rabe et al 2007). The potential role of repair processes in COPD has begun to be addressed only recently and is still poorly understood.
###end p 10
###begin p 11
###xml 286 296 286 296 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b14-copd-3-719">Mason 2002</xref>
###xml 298 314 298 314 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b7-copd-3-719">Bonay et al 2005</xref>
###xml 521 531 521 531 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b14-copd-3-719">Mason 2002</xref>
###xml 600 619 600 619 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b27-copd-3-719">Sugahara et al 1998</xref>
###xml 650 666 650 666 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b26-copd-3-719">Stern et al 2000</xref>
###xml 693 700 693 700 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 759 779 759 779 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b24-copd-3-719">Shigemura et al 2005</xref>
###xml 816 831 816 831 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b11-copd-3-719">Dohi et al 2000</xref>
###xml 921 937 921 937 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b28-copd-3-719">Ulich et al 1994</xref>
###xml 958 977 958 977 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b6-copd-3-719">Boismenu et al 1994</xref>
###xml 1033 1049 1033 1049 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b26-copd-3-719">Stern et al 2000</xref>
###xml 1102 1118 1102 1118 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b30-copd-3-719">Welsh et al 2000</xref>
###xml 537 543 <span type="species:ncbi:9606">humans</span>
###xml 1025 1031 <span type="species:ncbi:9606">humans</span>
Growth factors are key controllers of repair. In the lungs, hepatocyte growth factor (HGF) and keratinocyte growth factor (KGF), also known as fibroblast growth factor-7, are particularly relevant due to their capacity to stimulate alveolar and bronchial epithelial cell proliferation (Mason 2002; Bonay et al 2005). HGF is a multifunctional heterodimeric protein with mitogenic properties that is synthesized by a variety of lung cell types, including fibroblasts, macrophages, smooth muscle cells and epithelial cells (Mason 2002). In humans, HGF expression increases in serum after pneumonectomy (Sugahara et al 1998) and acute lung injury (ALI) (Stern et al 2000). In experimental animals in vivo gene transfection of HGF ameliorates pulmonary emphysema (Shigemura et al 2005) and drug-induced pulmonary injury (Dohi et al 2000). On the other hand, KGF is a heparin-binding mitogen secreted primarily by fibroblasts (Ulich et al 1994) and T lymphocytes (Boismenu et al 1994). Like HGF, KGF increases after lung injury in humans (Stern et al 2000) and minimizes lung injury in experimental animals (Welsh et al 2000).
###end p 11
###begin p 12
###xml 76 106 76 106 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b18-copd-3-719">Plantier and colleagues (2005)</xref>
###xml 244 271 244 271 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b7-copd-3-719">Bonay and colleagues (2005)</xref>
###xml 627 646 627 646 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b29-copd-3-719">Verghese et al 1998</xref>
###xml 648 665 648 665 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b23-copd-3-719">Sekine et al 2004</xref>
###xml 749 766 749 766 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b1-copd-3-719">Agusti et al 2003</xref>
###xml 154 162 <span type="species:ncbi:9606">patients</span>
###xml 487 495 <span type="species:ncbi:9606">patients</span>
The role of HGF and KGF in COPD has been addressed by two previous studies. Plantier and colleagues (2005) found that cultured fibroblasts harvested from patients with emphysema produced less HGF (but similar amounts of KGF) than controls, and Bonay and colleagues (2005) found a direct relationship between the severity of airflow obstruction and HGF mRNA content in lung samples of smokers. These two studies suggest, therefore, that the pulmonary regulation of HGF may be abnormal in patients with COPD. However, both HGF and KGF can also be released by extrapulmonary organs, thus having the potential to act systemically (Verghese et al 1998; Sekine et al 2004). Given the current clinical relevance attributed to the systemic effects of COPD (Agusti et al 2003), in this study we compared the levels of HGF and KGF in the pulmonary (bronchoalveolar lavage [BAL] fluid) and systemic compartment (circulating blood) of smokers with and without COPD and never smokers.
###end p 12
###begin title 13
Methods
###end title 13
###begin title 14
Subjects and ethics
###end title 14
###begin p 15
###xml 48 63 48 63 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b20-copd-3-719">Rabe et al 2007</xref>
###xml 14 22 <span type="species:ncbi:9606">patients</span>
###xml 310 318 <span type="species:ncbi:9606">patients</span>
###xml 513 521 <span type="species:ncbi:9606">patients</span>
###xml 757 765 <span type="species:ncbi:9606">patients</span>
###xml 856 864 <span type="species:ncbi:9606">patients</span>
###xml 999 1011 <span type="species:ncbi:9606">participants</span>
We studied 18 patients with COPD (GOLD II-III) (Rabe et al 2007), 18 smokers without chronic bronchitis or dyspnea and with normal lung function, and 8 never smokers. All of them required bronchoscopy for clinical purposes mainly to evaluate a solitary pulmonary nodule or a hemoptysis episode in the group of patients with COPD and smokers with normal lung function. The percentage of lung neoplasms was similar in both groups. In the never smoker group, the main indication was hemoptysis or chronic cough. All patients with COPD had not had any exacerbation for at least the three months that preceded their inclusion in the study. All of them were treated with inhaled bronchodilators (salmeterol, salbutamol, ipratropium bromide, and/or tiotropium); 4 patients also received inhaled corticosteroids (ICS), but none received oral steroids. We excluded patients with other chronic lung diseases (asthma, bronchiectasis, and interstitial lung diseases) and cardiac, hepatic, or renal failure. All participants signed an informed consent. The Ethics Committee of our institution approved the study protocol.
###end p 15
###begin title 16
Lung function
###end title 16
###begin p 17
###xml 98 106 98 106 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b3-copd-3-719">ATS 1995</xref>
###xml 180 195 180 195 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b21-copd-3-719">Roca et al 1986</xref>
###xml 84 96 <span type="species:ncbi:9606">participants</span>
A forced spirometry (GS, Warren E. Collins, Braintree, MA, USA) was obtained in all participants (ATS 1995). Spirometric reference values were those of a Mediterranean population (Roca et al 1986).
###end p 17
###begin title 18
Blood analysis
###end title 18
###begin p 19
A peripheral venous blood sample (10 cc) was obtained before bronchoscopy by venipuncture from an ante-cubital vein. Samples were immediately centrifuged at 1200 g during 10 minutes. Thereafter, serum samples were frozen in aliquots at -80 degreesC until analysis. All serum samples were processed identically and analyzed simultaneously at the completion of the study.
###end p 19
###begin title 20
Bronchoscopy
###end title 20
###begin p 21
###xml 384 399 384 399 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b19-copd-3-719">Pons et al 2005</xref>
###xml 316 328 <span type="species:ncbi:9606">participants</span>
Bronchoscopy was performed with a flexible fiberoptic bronchoscope (Pentax 15v, Tokyo, Japan). Active smokers were requested to refrain from smoking for at least 12 hours before bronchoscopy. This was checked by the exhaled carbon monoxide (CO) concentration (ToxCO, Bedfont, UK), which was lower than 10 ppm in all participants. BAL was performed following the standard methodology (Pons et al 2005). In brief, we instilled eight 25 mL aliquots (n = 8) of sterile saline solution in one pulmonary segment of one of the middle lobe or lingula not containing any visible lung nodule or infiltrate. Aliquots were placed in plastic recipients and immediately centrifuged at 200 x g for 10 min (at 4 degreesC), and the supernatant was stored at -80 degreesC until analysis.
###end p 21
###begin p 22
###xml 172 192 172 192 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b31-copd-3-719">Wimberley et al 1982</xref>
###xml 242 243 242 243 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 258 270 <span type="species:ncbi:9606">participants</span>
We excluded the presence of airway bacterial infection by using a protected specimen brush (PSB) (Mill-Rose Lab, Mentor OH, USA) to sample bronchial secretions before BAL (Wimberley et al 1982). The culture of PBS samples yielded less than 103 CFU/mL in all participants.
###end p 22
###begin title 23
Measurement of HGF and KGF
###end title 23
###begin p 24
###xml 468 484 468 484 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b22-copd-3-719">Sakai et al 1997</xref>
The concentration of HGF and KGF in BAL supernatant and serum was measured using a commercially available sandwich enzyme-linked immunosorbent assay (ELISA) kits (Amersham Pharmacia Biotech UK Ltd, Bucks, UK) following the manufacturer's directions (Amersham Pharmacia Biotech UK Ltd). The detection limits of HGF and KGF were 40 pg/ml and 15 pg/ml respectively. HGF and KGF concentrations were corrected for the albumin concentration in BAL like in previous studies (Sakai et al 1997).
###end p 24
###begin title 25
Statistical analysis
###end title 25
###begin p 26
Demographic are expressed as mean +/- standard deviation (SD) and biological data as median and range values. One way analysis of variance (ANOVA), followed by post-hoc contrast (Scheffe test) if appropriate, was used to assess the statistical significance of the differences between groups. Correlations between variables of interest were explored using the Spearman test. A p value lower than 0.05 was considered significant.
###end p 26
###begin title 27
Results
###end title 27
###begin title 28
Anthropometric and functional data
###end title 28
###begin p 29
###xml 0 7 0 7 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t1-copd-3-719">Table 1</xref>
###xml 167 174 167 174 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t1-copd-3-719">Table 1</xref>
###xml 65 77 <span type="species:ncbi:9606">participants</span>
###xml 147 155 <span type="species:ncbi:9606">patients</span>
###xml 188 196 <span type="species:ncbi:9606">patients</span>
Table 1 presents the main clinical and lung function data of all participants. Age was similar in the three groups. Smoking exposure was higher in patients with COPD (Table 1). On average patients with COPD showed moderate airflow obstruction whereas, by definition, spirometry was normal in smokers with normal lung function and never smokers.
###end p 29
###begin title 30
BAL cell count
###end title 30
###begin p 31
###xml 71 72 71 72 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sup>
###xml 112 113 112 113 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sup>
###xml 207 208 207 208 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sup>
###xml 333 340 333 340 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t2-copd-3-719">Table 2</xref>
###xml 137 145 <span type="species:ncbi:9606">Patients</span>
Total cell count was higher in smokers with normal lung function 2 x 105/mL [0.4-7] than in nonsmokers (0.5 x 105/mL [0.4-1], p < 0.05). Patients with COPD also showed a trend towards higher values (1.1 x 105/mL [0.5-3.3]) but differences failed to reach statistical significance. Differential cell counts were similar among groups (Table 2).
###end p 31
###begin title 32
HGF and KGF concentrations
###end title 32
###begin p 33
###xml 277 285 277 285 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f1-copd-3-719">Figure 1</xref>
###xml 686 694 686 694 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f2-copd-3-719">Figure 2</xref>
###xml 97 105 <span type="species:ncbi:9606">patients</span>
###xml 602 610 <span type="species:ncbi:9606">patients</span>
The concentration of HGF (corrected for albumin, HGF/albumin) in BAL was significantly higher in patients with COPD (62 pg/mg of albumin [13-184], p < 0.01) than in smokers with normal lung function (6.3 pg/mg of albumin [1-14]) and never smokers (14 pg/mg of albumin [4-25]) (Figure 1). There were no significant differences in albumin concentration in BAL in all groups: COPD, 21 mg/ml (7.6-44.3); Smokers 19 mg/ml (9-38 mg/ml); and, never smokers 11 mg/ml (7-16). In contrast, the serum concentration of HGF was higher (p < 0.01) in smokers with normal lung function (1897 pg/ml [433-2692]) than in patients with COPD (1053 pg/ml [629-1630]) and never smokers (700 pg/ml [424-986]) (Figure 2).
###end p 33
###begin p 34
###xml 82 90 <span type="species:ncbi:9606">patients</span>
###xml 208 220 <span type="species:ncbi:9606">participants</span>
The concentration of KGF in BAL was undetectable in most individuals. Likewise, 9 patients with COPD and 9 smokers with normal lung function showed undetectable levels of KGF in their serum. In the remaining participants, KGF levels were 70 pg/ml (27-553) (COPD) and 463 pg/ml (32-621) (smokers) (p = 0.09). All nonsmokers showed undetectable values.
###end p 34
###begin title 35
Effect of inhaled corticosteroids
###end title 35
###begin p 36
###xml 10 18 <span type="species:ncbi:9606">patients</span>
Only four patients with COPD were receiving therapy with ICS, and results did not change after removing them from the analysis.
###end p 36
###begin title 37
Effect of smoking
###end title 37
###begin p 38
###xml 179 187 <span type="species:ncbi:9606">patients</span>
###xml 515 523 <span type="species:ncbi:9606">patients</span>
As mentioned in methods, all current smokers (irrespective of the presence or absence of airflow obstruction) refrained from smoking for at least 12 hours before bronchoscopy. In patients with COPD we compared the levels of HGF and KGF in current smokers (n = 6) and exsmokers (n = 12), but we were unable to find any significant difference in HGF levels (BAL, 62 pg/mg albumin [13-156] vs. 58 pg/mg albumin (15-184); serum, 1057 pg/ml (629-1406) vs 1057 pg/ml (703-1629), respectively). Due to the small number of patients with detectable levels of KGF, we could not compare KGF values in these two subgroups of subjects.
###end p 38
###begin title 39
Physiological correlates
###end title 39
###begin p 40
###xml 374 382 <span type="species:ncbi:9606">patients</span>
We explored potential relationships between HGF and KGF levels and several variables of interest, such as age, body mass index, severity of airflow obstruction and total and differential cell counts of the BAL but were not able to find any significant relationship. There were no significant relationships between BAL and plasma HGF or KGF concentrations. Likewise, because patients with COPD had a higher smoking exposure we investigated the potential correlation between the latter (pack-yrs) and growth factor concentrations but were unable to find them.
###end p 40
###begin title 41
Discussion
###end title 41
###begin p 42
###xml 318 327 318 327 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f1-copd-3-719">Figures 1</xref>
###xml 332 333 332 333 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f2-copd-3-719">2</xref>
###xml 110 118 <span type="species:ncbi:9606">patients</span>
###xml 247 255 <span type="species:ncbi:9606">patients</span>
This study compares the pulmonary and systemic concentrations of two key lung growth factors (HGF and KGF) in patients with COPD, smokers with normal lung function and never smokers. We found that HGF levels were significantly increased in BAL in patients with COPD, and in serum in smokers with normal lung function (Figures 1 and 2). In contrast we were not able to find significant differences in KGF levels between these three groups, neither in blood nor in BAL.
###end p 42
###begin p 43
###xml 215 245 215 245 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b18-copd-3-719">Plantier and colleagues (2005)</xref>
###xml 327 335 327 335 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 534 542 534 542 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 616 623 616 623 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 880 907 880 907 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b7-copd-3-719">Bonay and colleagues (2005)</xref>
###xml 1094 1102 1094 1102 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f1-copd-3-719">Figure 1</xref>
###xml 1245 1266 1245 1266 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b13-copd-3-719">Kranenburg et al 2005</xref>
###xml 1326 1342 1326 1342 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b10-copd-3-719">Cheng et al 2008</xref>
###xml 1422 1438 1422 1438 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b7-copd-3-719">Bonay et al 2005</xref>
###xml 1440 1461 1440 1461 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b13-copd-3-719">Kranenburg et al 2005</xref>
###xml 1463 1479 1463 1479 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b10-copd-3-719">Cheng et al 2008</xref>
###xml 1868 1884 1868 1884 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b26-copd-3-719">Stern et al 2000</xref>
###xml 1898 1914 1898 1914 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b2-copd-3-719">Amano et al 2004</xref>
###xml 1954 1970 1954 1970 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b30-copd-3-719">Welsh et al 2000</xref>
###xml 95 103 <span type="species:ncbi:9606">patients</span>
###xml 205 213 <span type="species:ncbi:9606">patients</span>
###xml 284 292 <span type="species:ncbi:9606">patients</span>
###xml 688 696 <span type="species:ncbi:9606">patients</span>
###xml 806 814 <span type="species:ncbi:9606">patients</span>
###xml 1306 1314 <span type="species:ncbi:9606">patients</span>
###xml 1563 1571 <span type="species:ncbi:9606">patients</span>
###xml 2136 2143 <span type="species:ncbi:4097">tobacco</span>
To our knowledge this is the first study that evaluates HGF and KGF levels in BAL and serum in patients with COPD. Two previous studies however have investigated the potential role of HGF and KGF in these patients. Plantier and colleagues (2005) found that fibroblasts harvested from patients with pulmonary emphysema produced in vitro less HGF but similar KGF levels than healthy smokers and nonsmokers. This may seem at variance with our results. Two factors can contribute to explain this apparent discrepancy. First, they studied in vitro the response of a specific cell type (the fibroblast) whereas we studied in vivo the end result of a variety of cell types. Second, they studied patients with very severe COPD who required lung volume reduction surgery or lung transplantation, whereas we studied patients with, mostly, moderate disease. In contrast, the second study by Bonay and colleagues (2005) reported a direct relationship between the degree of airflow obstruction and HGF mRNA in lung tissue of smokers with and without COPD, which seem to agree with the results of our study (Figure 1). Interestingly, other growth factors, such as fibroblast growth factor (FGF) -1 and -2 appear also to be increased in bronchial airway wall (Kranenburg et al 2005) and placental growth factor in BAL in patients with COPD (Cheng et al 2008). Therefore, the results of our study in combination with other previous ones (Bonay et al 2005; Kranenburg et al 2005; Cheng et al 2008) seem to indicate that a variety of growth factors are upregulated in the lungs of patients with COPD. In principle, this is consistent with an active repair response. Yet, lung function deteriorates rapidly in COPD, indicating that this response may not fully effective. This is not the case in other conditions characterized by lung injury, such as acute respiratory distress syndrome (Stern et al 2000), pneumonia (Amano et al 2004), and ventilation induced lung injury (Welsh et al 2000), where a similar HGF response has been described. It is possible that differences are related to the chronic and repetitive nature of tissue injury in COPD (mostly tobacco smoking). However, given that the levels of HGF in BAL were not different in active smokers and ex-smokers with COPD, we hypothesize that lung repair may be insufficient or inadequate in COPD.
###end p 43
###begin p 44
###xml 218 234 218 234 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b22-copd-3-719">Sakai et al 1997</xref>
###xml 236 253 236 253 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b12-copd-3-719">Jaffre et al 2002</xref>
###xml 460 477 460 477 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b12-copd-3-719">Jaffre et al 2002</xref>
###xml 510 526 510 526 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b22-copd-3-719">Sakai et al 1997</xref>
###xml 601 612 601 612 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b4-copd-3-719">Barnes 2004</xref>
Previous published studies have shown a relationship between HGF and neutrophil count in BAL fluid in different pulmonary diseases, suggesting that alveolar neutrophils play a major role in HGF production in the lung (Sakai et al 1997; Jaffre et al 2002). In contrast, we did not find such a correlation. This discrepancy could be due to the fact that previous studies evaluated different diseases (with different pathogeny) such as acute respiratory failure (Jaffre et al 2002) and interstitial lung disease (Sakai et al 1997). It is likely that the response to lung injury in COPD may be different (Barnes 2004) and include activated cells, cytokines, and oxidative stress that were not measured in the present study.
###end p 44
###begin p 45
###xml 102 123 102 123 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b32-copd-3-719">Yamanouchi et al 1998</xref>
###xml 125 141 125 141 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b26-copd-3-719">Stern et al 2000</xref>
###xml 241 249 <span type="species:ncbi:9606">patients</span>
Studies in control subjects were unable to detect HGF in BAL fluid or its concentration was very low (Yamanouchi et al 1998; Stern et al 2000). This is also at variance with our results, because our controls were not healthy individuals and patients that required a bronchoscopy for a variety of clinical reasons.
###end p 45
###begin p 46
###xml 39 56 39 56 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b1-copd-3-719">Agusti et al 2003</xref>
###xml 123 133 123 133 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b14-copd-3-719">Mason 2002</xref>
###xml 135 154 135 154 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b25-copd-3-719">Steiling et al 2004</xref>
###xml 315 334 315 334 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b27-copd-3-719">Sugahara et al 1998</xref>
###xml 346 361 346 361 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b9-copd-3-719">Chen et al 2006</xref>
###xml 457 476 457 476 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b8-copd-3-719">Borawski et al 2002</xref>
###xml 478 494 478 494 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b16-copd-3-719">Ozden et al 2004</xref>
###xml 512 541 512 541 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b17-copd-3-719">Palange and colleagues (2006)</xref>
###xml 769 776 769 776 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t1-copd-3-719">Table 1</xref>
###xml 784 813 784 813 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b17-copd-3-719">Palange and colleagues (2006)</xref>
###xml 971 979 971 979 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f2-copd-3-719">Figure 2</xref>
###xml 1534 1553 1534 1553 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b18-copd-3-719">Plantier et al 2005</xref>
###xml 1787 1806 1787 1806 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b29-copd-3-719">Verghese et al 1998</xref>
###xml 586 594 <span type="species:ncbi:9606">patients</span>
###xml 865 873 <span type="species:ncbi:9606">patients</span>
###xml 1217 1225 <span type="species:ncbi:9606">patients</span>
Because COPD has a systemic component (Agusti et al 2003), and both HGF and KGF are also secreted by extrapulmonary cells (Mason 2002; Steiling et al 2004), it was also of interest to to analyze their concentration in serum. Previous investigations have reported that serum HGF levels increase after pneumonectomy (Sugahara et al 1998), smoking (Chen et al 2006) and in several acute and chronic disorders such as liver, kidney, and cardiovascular disease (Borawski et al 2002; Ozden et al 2004). More recently, Palange and colleagues (2006) found increased HGF serum concentrations in patients with COPD compared to never smokers. This latter observation fully agrees with our results, albeit we extend their observations to include smokers with normal lung function (Table 1). Like Palange and colleagues (2006) we found that HGF serum levels were higher in COPD patients than in never smokers, but this increase was much enhanced in smokers with normal lung function (Figure 2). This may suggest a blunted systemic response that may potentially limit lung repair. Alternatively, a decreased systemic level of HGF compared to smokers with normal lung function may also reflect increased consumption in the lungs of patients with COPD. In contrast to HGF findings, we do not find significant differences in KGF levels between groups, neither in BAL or blood, because most values were below the detection limit of the technique. We do not think that this is due to technical reasons because we used same methodology used in previous (Plantier et al 2005). Alternatively, given that the three groups of subjects studied showed very low KGF levels, this may indicate that KGF is not involved in the pathogenesis of smoking related diseases, at variance with other disease states like ALI (Verghese et al 1998).
###end p 46
###begin p 47
###xml 116 131 116 131 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b9-copd-3-719">Chen et al 2006</xref>
###xml 683 698 683 698 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b9-copd-3-719">Chen et al 2006</xref>
###xml 856 871 856 871 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b9-copd-3-719">Chen et al 2006</xref>
###xml 1087 1108 1087 1108 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b5-copd-3-719">Blanquaert et al 2000</xref>
###xml 1260 1277 1260 1277 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b15-copd-3-719">Nayeri et al 2002</xref>
###xml 152 164 <span type="species:ncbi:9606">participants</span>
###xml 295 307 <span type="species:ncbi:9606">participants</span>
###xml 325 333 <span type="species:ncbi:9606">patients</span>
###xml 578 586 <span type="species:ncbi:9606">patients</span>
###xml 771 779 <span type="species:ncbi:9606">patients</span>
###xml 1156 1164 <span type="species:ncbi:9606">patients</span>
Several methodological aspects of our study deserve comment. First, because it is known that smoking increases HGF (Chen et al 2006), we confirmed that participants refrained from smoking 12 hours before bronchoscopy by measuring the exhaled CO concentration (which was lower than 10 ppm in all participants). Second, albeit patients with COPD had higher smoking exposure that smokers with normal lung function we do not believe that this influenced our results because we did not find any correlation between smoking exposure (pack-yrs) and levels of growth factors. Third, in patients with lung cancer, an overexpression of HGF in lung tissue close to the tumor has been reported (Chen et al 2006). Yet, we think that this did not biased our results because we studied patients with Stage I lung cancer in whom the over expression of HGF is negligible ( Chen et al 2006), BAL was always performed in the lung without chest X-ray anomalies and HGF levels were not different in smokers with and without cancer. Fourth, although steroids can modulate the concentration of growth factors (Blanquaert et al 2000), results were unchanged after excluding the 4 patients treated with ICS. Likewise, although infection can also influence growth factor concentration (Nayeri et al 2002), we excluded this potential confounding effect on the basis of negative cultures of PBS samples.
###end p 47
###begin title 48
Conclusion
###end title 48
###begin p 49
###xml 92 100 <span type="species:ncbi:9606">patients</span>
###xml 301 309 <span type="species:ncbi:9606">patients</span>
Our study reports that the levels of HGF (but not those of KGF) in BAL fluid were higher in patients with COPD than in smokers with normal lung function or never smokers. Interestingly, these results were not mirrored in the systemic circulation, where only smokers with normal lung function (but not patients with COPD) were able to mount a vigorous HGF response. Overall, these results address a still poorly understood but potentially very relevant area of repair in COPD, the true therapeutic holy grail in this devastating and progressive disease.
###end p 49
###begin title 50
Acknowledgments
###end title 50
###begin p 51
The authors thank the participating individuals for their collaboration in the study and Francesca Bauza and Angels Noguera for their help during the study. This study was supported in part by SEPAR-2002.
###end p 51
###begin title 52
References
###end title 52
###begin article-title 53
Systemic effects of chronic obstructive pulmonary disease
###end article-title 53
###begin article-title 54
Essential contribution of monocyte chemoattractant protein-1/C-C chemokine ligand-2 to resolution and repair processes in acute bacterial pneumonia
###end article-title 54
###begin article-title 55
Standardization of Spirometry, 1994 Update. American Thoracic Society
###end article-title 55
###begin article-title 56
Mediators of chronic obstructive pulmonary disease
###end article-title 56
###begin article-title 57
Cortisol inhibits hepatocyte growth factor/scatter factor expression and induces c-met transcripts in osteoblasts
###end article-title 57
###begin article-title 58
Modulation of epithelial cell growth by intraepithelial gamma delta T cells
###end article-title 58
###begin article-title 59
###xml 66 71 <span type="species:ncbi:9606">human</span>
Hepatocyte and keratinocyte growth factors and their receptors in human lung emphysema
###end article-title 59
###begin article-title 60
###xml 154 162 <span type="species:ncbi:9606">patients</span>
Serum hepatocyte growth factor is associated with viral hepatitis, cardiovascular disease, erythropoietin treatment, and type of heparin in haemodialysis patients
###end article-title 60
###begin article-title 61
Cigarette smoking induces overex-pression of hepatocyte growth factor in type II pneumocytes and lung cancer cells
###end article-title 61
###begin article-title 62
Increased expression of placenta growth factor in COPD
###end article-title 62
###begin article-title 63
###xml 63 69 <span type="species:ncbi:10090">murine</span>
Hepatocyte growth factor attenuates collagen accumulation in a murine model of pulmonary fibrosis
###end article-title 63
###begin article-title 64
Hepatocyte growth factor is produced by blood and alveolar neutrophils in acute respiratory failure
###end article-title 64
###begin article-title 65
Chronic obstructive pulmonary disease is associated with enhanced bronchial expression of FGF-1, FGF-2, and FGFR-1
###end article-title 65
###begin article-title 66
Hepatocyte growth factor. The key to alveolar septation?
###end article-title 66
###begin article-title 67
Hepatocyte growth factor may act as an early therapeutic predictor in pneumonia
###end article-title 67
###begin article-title 68
###xml 34 42 <span type="species:ncbi:9606">patients</span>
Hepatocyte growth factor (HGF) in patients with hepatitis B and meningitis
###end article-title 68
###begin article-title 69
Circulating haemopoietic and endothelial progenitor cells are decreased in COPD
###end article-title 69
###begin article-title 70
###xml 64 69 <span type="species:ncbi:9606">human</span>
Defect of hepatocyte growth factor production by fibroblasts in human pulmonary emphysema
###end article-title 70
###begin article-title 71
Blunted gamma delta T-lymphocyte response in chronic obstructive pulmonary disease
###end article-title 71
###begin article-title 72
Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary
###end article-title 72
###begin article-title 73
Spirometric reference values for a Mediterranean population
###end article-title 73
###begin article-title 74
###xml 71 79 <span type="species:ncbi:9606">patients</span>
Hepatocyte growth factor in bronchoalveolar lavage fluids and cells in patients with inflammatory chest diseases of the lower respiratory tract: detection by RIA and in situ hybridization
###end article-title 74
###begin article-title 75
Plasma hepatocyte growth factor is increased in early-phase sepsis
###end article-title 75
###begin article-title 76
###xml 98 102 <span type="species:ncbi:10116">rats</span>
Amelioration of pulmonary emphysema by in vivo gene transfection with hepatocyte growth factor in rats
###end article-title 76
###begin article-title 77
Activated hepatic stellate cells express keratinocyte growth factor in chronic liver disease
###end article-title 77
###begin article-title 78
###xml 127 135 <span type="species:ncbi:9606">patients</span>
Keratinocyte growth factor and hepatocyte growth factor in bronchoalveolar lavage fluid in acute respiratory distress syndrome patients
###end article-title 78
###begin article-title 79
###xml 19 24 <span type="species:ncbi:9606">human</span>
###xml 65 73 <span type="species:ncbi:9606">patients</span>
Elevation of serum human hepatocyte growth factor (HGF) level in patients with pneumonectomy during a perioperative period
###end article-title 79
###begin article-title 80
Keratinocyte growth factor is a growth factor for type II pneumocytes in vivo
###end article-title 80
###begin article-title 81
###xml 88 96 <span type="species:ncbi:9606">patients</span>
Hepatocyte growth factor and keratinocyte growth factor in the pulmonary edema fluid of patients with acute lung injury. Biologic and clinical significance
###end article-title 81
###begin article-title 82
###xml 81 84 <span type="species:ncbi:10116">rat</span>
Keratinocyte growth factor prevents ventilator-induced lung injury in an ex vivo rat model
###end article-title 82
###begin article-title 83
Use of a bronchoscopic protected catheter brush for the diagnosis of pulmonary infections
###end article-title 83
###begin article-title 84
###xml 85 93 <span type="species:ncbi:9606">patients</span>
Measurement of hepatocyte growth factor in serum and bronchoalveolar lavage fluid in patients with pulmonary fibrosis
###end article-title 84
###begin p 85
HGF concentration in BAL in the three groups of individuals studied.
###end p 85
###begin p 86
###xml 0 14 0 14 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Abbreviations:</bold>
Abbreviations: BAL, bronchoalveolar lavage; HGF, hepatocyte growth factor.
###end p 86
###begin p 87
HGF concentration in serum in the three groups of individuals studied.
###end p 87
###begin p 88
###xml 0 13 0 13 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Abbreviation:</bold>
Abbreviation: HGF, hepatocyte growth factor.
###end p 88
###begin p 89
###xml 38 41 38 39 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#177;</bold>
###xml 53 65 <span type="species:ncbi:9606">participants</span>
Clinical and lung function data (mean +/- SD) of all participants
###end p 89
###begin p 90
###xml 0 6 0 6 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Notes:</bold>
Notes: p < 0.01 (vs nonsmokers);
###end p 90
###begin p 91
p < 0.05 (vs smokers with normal lung function).
###end p 91
###begin p 92
###xml 0 14 0 14 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Abbreviations:</bold>
###xml 63 64 63 64 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
Abbreviations: COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume in one second; FVC, forced vital capacity; SD, standard deviation.
###end p 92
###begin p 93
Bronchoalveolar lavage fluid total and differential cell counts (Median and range)
###end p 93
###begin p 94
###xml 0 6 0 6 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Notes:</bold>
Notes: p < 0.05 vs nonsmokers.
###end p 94
###begin p 95
###xml 0 13 0 13 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Abbreviation:</bold>
Abbreviation: COPD, chronic obstructive pulmonary disease.
###end p 95

